A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have activity in acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (ITD) mutations, but efficacy is limited by resistance-conferring kinase domain mutations. This phase 1/2 study evaluated the safety, toler...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Smith, Catherine C., Levis, Mark J., Frankfurt, Olga, Pagel, John M., Roboz, Gail J., Stone, Richard M., Wang, Eunice S., Severson, Paul L., West, Brian L., Le, Mai H., Kayser, Sabine, Lam, Bao, Hsu, Henry H., Zhang, Chao, Bollag, Gideon, Perl, Alexander E.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189289/
https://ncbi.nlm.nih.gov/pubmed/32330242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001449
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky